Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

Fig. 2

Effects of survivin/BIRC expression on RCC patient survival probability: Kaplan-Meier survival analyses of overall survival (OS) from TCGA-RCC cohorts of ccRCC (A), chRCC (B) and pRCC (C) were presented. Patients were grouped into the high survivin expression group versus the low survivin expression group based on the median mRNA expression of the BIRC5/survivin gene. Each p-value for the significance from high versus low BIRC5/survivin gene expression was calculated using the log-rank test. The figures were performed using R version 4.0.3

Back to article page